Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

LGD-6972 · MB-11262

Small molecule · developed by Ligand Pharmaceuticals

Phase 2 Most advanced trial (none active)
LGND Developer
3 Registered trials

What is LGD-6972?

LGD-6972 (also coded MB-11262) is a sodium salt powder formulated in Captisol, a sulfobutylether beta-cyclodextrin excipient. It is studied in type 2 diabetes mellitus.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
MB-11262
Drug type
Small molecule
Therapy area
Metabolic
Developer
Ligand Pharmaceuticals (LGND)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
6IJ842I0Z2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02851849 Phase 2 Type 2 Diabetes Mellitus Completed LGND
NCT02672839 Phase 1 Type 2 Diabetes Mellitus (T2DM) Completed LGND
NCT02250222 Phase 1 Type 2 Diabetes Mellitus Completed LGND

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Type 2 Diabetes MellitusType 2 Diabetes Mellitus (T2DM)

More from Ligand Pharmaceuticals

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the LGND page.

Follow LGND, the company behind LGD-6972

See LGND's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

LGND catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.